Teresa Semeraro

This inventor holds 8 USPTO granted patents and 2 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Indivior UK Limited, Chronos Therapeutics Limited. Active years: 2018-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Teresa Semeraro. Retrieved from https://idiyas.com/inventor/teresa-semeraro

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Verano, IT (2020)
Verona, IT (2018 - 2023)

Company Filing History:

Chronos Therapeutics Limited

patents

Years Active: 2018-2023

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11660293 - Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists (2023-05-30),

2. 10654842 - Dopamine Dreceptor antagonist compounds (2020-05-19),

3. 10584135 - Substituted 3,6-diazabicyclo[3.2.0]heptanes (2020-03-10),

4. 10577361 - Dopamine D3 receptor antagonists having a morpholine moiety (2020-03-03),

5. 10273244 - Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators (2019-04-30),

6. 10000477 - Dopamine D3 receptor antagonist compounds (2018-06-19),

7. 9920053 - N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system (2018-03-20),

8. 9908897 - Spirocyclic derivatives (2018-03-06),

Title: The Innovative Contributions of Teresa Semeraro

Introduction

Teresa Semeraro is a prominent inventor based in Verona, Italy, known for her significant contributions to the field of pharmaceutical sciences. With a total of eight patents to her name, she has made remarkable strides in developing compounds that target various neurological and psychological disorders. Her work is characterized by a commitment to advancing therapeutic options for patients in need.

Latest Patents

Among her latest patents, Teresa has developed substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists. These compounds are designed to act as antagonists of the orexin-1 and orexin-2 receptors, which are crucial in the treatment and prevention of conditions such as substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment, and Alzheimer's disease. Additionally, she has worked on novel dopamine D3 receptor antagonist compounds, focusing on their preparation processes, intermediates, and therapeutic applications, particularly in treating drug dependency and psychosis.

Career Highlights

Teresa has had a successful career, working with notable companies such as Indivior UK Limited and Chronos Therapeutics Limited. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research and development.

Collaborations

Throughout her career, Teresa has collaborated with esteemed colleagues, including Fabrizio Micheli and Susanna Cremonesi. These partnerships have fostered an environment of innovation and have been instrumental in advancing her research initiatives.

Conclusion

Teresa Semeraro's contributions to the field of pharmaceuticals are noteworthy, as she continues to develop innovative solutions for complex health issues. Her dedication to research and collaboration exemplifies the spirit of innovation in the scientific community.

Profile summary based on public USPTO records.